The stock of Citius Pharmaceuticals Inc. (NASDAQ:CTXR) increased by $0.08 on Friday to finish at $0.97, up 8.28 percent. The last five days have seen an average of 411,200 shares of common stock traded. 17 times new highs were reached in the current year, with a gain of $0.1778. The average number of shares traded over the last 20 days was 1,303,730, while the average volume over the last 50 days totaled 1,671,872.
CTXR stock dropped -11.21% since last month. On 08/16/23, the company’s shares reached a one-month low of $0.8500. The stock touched a high of $1.71 on 04/17/23, after rallying from a low of $0.77 in 52 weeks. The price of CTXR stock has risen by 22.51% or $0.1778 this year, reaching a new high 17 times. Still, the stock price is down -43.40% from the 52-week high.
Financial Health
For the three months ended June 29, Citius Pharmaceuticals Inc.’s quick ratio was 7.10, while its current ratio was 7.10, indicating its ability to pay off its debt.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. CTXR’s return on assets (ROA) during the last 12 months has been -27.80%. In the meantime, the return on equity (ROE) for the last 12 months was -31.20%.
Earnings Surprise
According to Citius Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. It was predicted that Citius Pharmaceuticals Inc.’s quarterly earnings would be -$0.06, but it ended up being -$0.05. EBITDA was -$8.62 million for the quarter. At the end of Citius Pharmaceuticals Inc.’s most recent quarter ended June 29, its liabilities totaled 12.11 million, while its total debt was $0.53 million. Equity owned by shareholders amounts to $158.86 million.
Technical Picture
Here’s a quick look at Citius Pharmaceuticals Inc.’s (CTXR) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 55.53%, suggesting the stock is Neutral, with a 57.76% historical volatility rate.
The stochastic %K and %D were 38.19% and 32.12% respectively, while the average true range (ATR) was 0.0622. Based on the 14-day stochastic reading of 62.36%, the RSI (14) reading is 48.28%. On the 9-day MACD Oscillator, the stock is at 0.0212.
Analyst Ratings
In its analyst report released on November 30, 2021, Maxim Group began covering Citius Pharmaceuticals Inc. (NASDAQ: CTXR). The stock was rated as a Buy by the brokerage firm. Analysts have assigned Citius Pharmaceuticals Inc. (CTXR) an Buy rating. CTXR is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 3 others recommend it as a buy.
What is CTXR’s price target for the next 12 months?
The current consensus forecast for the stock is between $4.00 and $8.00, with a median target price of $4.00. In analyzing these forecasts, the average price target given by analysts for Citius Pharmaceuticals Inc. (CTXR) is $5.33.
